Determination of Different Antigenic Sites on the Adenovirus Hexon Using Monoclonal Antibodies

By

ÉVA ÁDÁM1, I. NÁSZ1, ANNA LENGYEL1, J. ERDEI2, and J. FACHET2

1 Institute of Microbiology, Semmelweis University Medical School, Budapest, and
2 Institute of Pathophysiology, University Medical School, Debrecen, Hungary

With 8 Figures

Accepted August 4, 1986

Summary

Eighteen mouse ascitic fluids containing monoclonal antibodies (MAbs) directed against crystallized hexon of adenovirus (AV) type 1 were used to map the antigenic structure of the capsomer in reciprocal competitive binding ELISA. With the help of peroxidase-labelled MAbs at least nine epitopes (epitope clusters) located on three distinct antigenic sites were identified on the hexon. Epitope on antigenic site I recognized by two MAbs could be the genus specific antigenic determinant based on the broad reactivity patterns of the MAbs. Epitopes on the antigenic site II recognized by fifteen MAbs could be divided into seven epitope clusters according to the competition patterns. Antigenic site III recognized by one MAb completely differs from the antigenic site I and on the basis of one-way blocking with all the MAbs specific for antigenic site II, should be also different from the latter one. The data suggest that the seven epitope clusters of antigenic site II contain partially overlapping epitopes and may be a part of a large single immunodominant antigenic region on AV 1 hexon as well as on hexons of heterologous types.

Introduction

Monoclonal antibodies have proven to be useful tools in determining the important antigenic regions of structural virus proteins. The introduction of the MAbs into the antigenic analysis of adenovirus hexon protein resulted the recognition that the capsomer has more complicated antigenic structure as was known earlier (5, 12, 13, 14, 18). Using a panel of MAbs produced against crystallized AV 1 hexon for the examination of purified heterologous
hexons it was demonstrated that on the surface of the hexon a large number of epitopes do exist, some of which are overlapping and characterized as interspecies specificities (2).

In the present paper, we report on the delineation of different antigenic sites and epitopes (epitope clusters) of the adenovirus hexon by means of competitive binding ELISA.

**Materials and Methods**

*Virus Strains, Purification of Hexons*

Human adenovirus types 1, 2, 5, and 6 (subgenus C), 8, 9, 10, and 13 (subgenus D), 12 (subgenus A), 7 and 35 (subgenus B) were used in the experiments for determining the cross-reactivity of the MAbs. All these strains were propagated on HEp-2 cells, and the soluble hexon proteins of all virus types were separated and purified as described earlier (9, 11).

*Hybridoma and Mouse Ascites Production*

Spleen cells of Balb/c mice immunized with crystallized AV 1 hexon were fused with Sp 2/0 myeloma cells. Hybrid cells producing specific MAbs were inoculated i.p. into mice, and the developed ascites was sucked from the abdomen. The reactivity patterns of the MAbs were determined with 11 different hexon types using indirect ELISA (2).

*Purification of Monoclonal IgG*

Saturated ammonium sulphate was added to the ascitic fluids to a final concentration of 40 per cent. After centrifugation at 2000 × g for 20 minutes, the pellet was resuspended in 40 per cent saturated ammonium sulphate. After three times repeated centrifugation, the pellet was resuspended in distilled water and dialysed against PBS pH 7.2, at 4°C, overnight.

*Peroxidase Labelling of Monoclonals*

MAbs were dialysed against 0.15 M NaCl and labelled with horseradish peroxidase (REANAL, Budapest) according to the technique of AVREMEAS and TERNYNCK (1). Briefly, 10 mg peroxidase were dissolved in 0.2 ml phosphate buffer pH 6.8 containing 1 per cent glutaraldehyde, incubated at room temperature for 18 hours, and passed through a Sephadex G-25 column. Brown-coloured fractions were collected and added to 5 mg of MAbs. The mixture was stored at 4°C for 24 hours, and dialysed extensively against PBS. Before competitive-binding assays, each conjugate was titrated by direct ELISA, and used in the competition experiments in predetermined dilutions with a resulting absorbance of approx. 1.4, measured at 492 nm.

*Competitive-binding ELISA*

Polystyrene plates (Novogen) were coated with purified AV 1 hexon (250 ng in 50 µl/well) in PBS pH 7.2, overnight. Nonspecific binding was reduced to a minimum by the addition of PBS-Tween 20 containing 0.5 per cent BSA (Serva, Heidelberg) for 1 hour. Dilutions of unlabelled competitor MAbs causing 100 per cent inhibition of the own labelled probe were the starting dilutions (dilution factor 1), and serial two-fold dilutions of competitor MAbs were added, followed immediately by the predetermined dilution of the labelled MAbs. The plates were incubated for 90 minutes at 37°C, then washed and the bound peroxidase-labelled MAbs were detected by adding 50 µl of ortho-phenylenediamine (OPD). The reaction was stopped by the addition of 50 µl of 4 M H₂SO₄ per well. Optical
density was determined at 492 nm with a Titertek Multiskan photometer. Since the non-specific binding of individual conjugates varied considerably, binding to control antigen (BSA) was taken to represent background, and binding of each conjugate to viral antigen as maximum binding. This difference was taken to represent 100 per cent binding, and the relative inhibition by the competing first antibody was normalized to this scale in each individual test. Results were expressed as a percentage of competition, and rated as complete inhibition if the first three dilutions caused more than 70 per cent reduction of absorbance, partial inhibition if the reduction was between 60 to 40 per cent and results were considered negative if the reduction of absorbance was not more than 40 per cent (17).

On the other hand, competitive-binding ELISA was performed with a mixture of labelled MAbs (designated 1A3, 2A1, 2A6, and 2B2) and different concentrations of purified hexon types preincubated at 37° C for 2 hours (6). The wells were coated with AV1 hexon (5 μg/ml) and the inhibiting ability of different hexon types was calculated as mentioned above.

**Results**

**Differentiation of Antigenic Sites on the Adenovirus Hexon**

Eighteen MAbs were used in unlabelled and peroxidase-labelled form to differentiate topographically distinct antigenic sites on AV1 hexon. The terminology of Golding and Gerhard (19) was used to define the epitopes and antigenic sites, i.e., an antigenic site consists of a cluster of epitopes, and the epitope is the combining site of a single MAb.

Three different antigenic sites could be separated on the basis of reciprocal competition experiments (Table 1). Epitope(s) of antigenic site I recognized by two MAbs is completely different from antigenic sites II and III, i.e., MAbs 1A3 and 2C2 cause complete inhibition of each other
|      | 1A 3 | 2C 2 | 2C 3 | 1D 4 | 1A 5 | 1D 2 | 2B 2 | 2C 6 | 2C 4 | 1B 2 | 2A 5 | 1A 6 | 2B 5 | 2C 1 | 2D 6 | 2A 1 | 2A 6 | H12 |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| I    | ●    | ●    |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| II/1 | 2C 3 |      | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |      |      |      | ●    |
|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| II/2 | 1D 2 |      | ●    | ●    |      |      |      |      |      |      |      |      |      |      |      |      |      |      | ●    |
|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| II/3 | 2C 6 |      | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |      |      |      | ●    |
|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| II/4 | 1A 6 |      | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |      |      |      | ●    |
|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| II/5 | 2D 6 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| II/6 | 2A 1 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| II/7 | 2A 6 |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| III  | H12  |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

**Table 1. Reciprocal competitive binding ELISA with 18 MAbs showing different competition patterns**

- **1A 3**: Peroxidase labelled MAbs
- **2C 2**: Competitor MAbs
- ● Complete inhibition
- × Partial inhibition
- - No inhibition
Antigenic Sites on the Adenovirus Hexon

Overlapping Epitope Clusters on Antigenic Site II

Epitopes on the antigenic site II could be clustered into seven groups based on complete and partial reciprocal inhibition (Table 1). MAbs of epitope cluster II/1 completely inhibit the binding of the MAbs II/2 to II/4, and partially inhibit the binding of MAbs specific for epitope clusters II/5 to II/7 (Fig. 3). This kind of competition patterns could characterize two larger groups of closely related epitopes. One of them could be the epitopes clustered as II/1 to II/4, and the other characterized as epitopes II/5 to II/7. The differentiation of epitope cluster II/2 to II/4 is based on the different partial reciprocal inhibition of the MAbs grouped into these clusters. MAbs of epitope cluster II/2 completely inhibit the binding of MAbs specific for epitopes of II/1, II/3 and II/4 in reciprocal fashion, but they can inhibit each
other partially (Fig. 4). MAbs of epitope cluster II/3 show another form of reciprocal competition, i.e., one of the MAbs (2 C 4) partially inhibits the binding of three other MAbs (2 C 6, 1 B 2 and 2 A 5), and the latter three MAbs completely inhibit each other (Fig. 5). MAbs specific for epitope cluster II/4 show similar inhibition patterns as those of epitope cluster II/3. It means, that one MAb of this group (2 B 5) could partially inhibit the binding of two other MAbs (1 A 6 and 2 C 1) showing reciprocal partial inhibition patterns, but the two latter MAbs completely inhibit the binding of each
Fig. 5. MAbs of epitope cluster II/3 (1B2, 2C6, and 2A5) show reciprocal partial inhibition with the fourth member of this epitope cluster (MAb 2C4), but complete inhibition with each other. • 2C6/1B2; ○ 2A5/2C6; ▽ 1B2/2C6; × 2C4/2C6; ▲ 2C4/1B2; ■ 2C4/2A5

other (Fig. 6). The differentiation of epitope clusters II/5 to II/7 is based on different complete and unidirectional blocking results. MAb specific for epitope cluster II/5 (2D6) could completely inhibit the binding of two MAbs of epitope cluster II/3 (MAbs 2C6 and 2A5), and of MAb 1A6 of epitope cluster II/4. MAb 2A1 (epitope cluster II/6) shows unidirectional complete inhibition of MAb 1A6 of epitope cluster II/4, while MAb 2A6 (epitope cluster II/7) shows reciprocal partial inhibition of all the MAbs clustered into II/1 to II/4 (Table 1). The three MAbs specific for epitope clusters II/5 to II/7 showed complete bidirectional inhibition of each other.

Fig. 6. Reciprocal competitive binding ELISA with MAbs specific for epitope clusters II/4. MAb 2B5 shows reciprocal partial inhibition with MAbs 1A6, and 2C1, but the latter ones inhibit each other completely. ● 1A6/2C1; ○ 2C1/1A6; ▽ 2B5/1A6; ■ 2B5/2C1
The Presence of Different Epitopes on Heterologous Hexons

For the determination of the presence of different AV 1 hexon related epitopes on the heterologous hexon types, four of the labelled MAbs (1A3, 2A1, 2A6, and 2B2) were mixed with serial dilutions (5 to 40 µg/ml) of different hexon types. After preincubation at 37°C 50 µl of each mixture was added to AV 1 hexon coated wells and the absorbances were determined both in the presence and in the absence of heterologous hexon types. Fig. 7 a–d shows the results with AV 1 hexon and with the heterologous hexons.
types of the same subgenus (types 2, 5, and 6). As can be seen, in the case of the MAbs 1 A 3, 2 A 1, and 2 A 6, each hexon types mixed with the MAbs causes nearly 100 per cent inhibition. The results with types 1, 2, and 6 were similar, when mixed MAb 2 B 2, while type 5 could not compete the binding of this MAb. The curves representing the competition with heterologous types of subgenus D (Fig. 8 a–c) only in the case of MAb 1 A 3 are similar to the types of subgenus C, and in high concentration of type 9 with MAbs 2 A 1, 2 A 6, and 2 B 2. Hexon types 8 and 10 could not cause complete inhibition even in high concentration.

Discussion

Eighteen MAbs were used in unlabelled and peroxidase-labelled form in reciprocal competitive binding ELISA to map the antigenic structure of the hexon. Each MAb was compared with all other MAbs and the inhibition patterns were characterized as complete or partial, bidirectional (reciprocal) or unidirectional (one-way) inhibition (4).

At least three antigenic sites (I to III) were determined on the base of the results, and seven epitope clusters (epitopes) could be separated on the antigenic site II. The two MAbs (1 A 3 and 2 C 2) specific for antigenic site I recognize the same epitope, i.e., the genus specific one. These MAbs have broad reactivity patterns, because they reacted with the hexons of all human AV types studied by ELISA and HA (2), and with bovine AV type 3 in gel precipitation experiment (3). Their specificity to sterically independent epitopes comparing to MAbs H 12, 2 A 1, and 1 B 2 were also demonstrated by gel diffusion experiments. MAb H 12, however reacted with all human AV types tested, failed to react with bovine AV type 3 both in ELISA and HA (unpublished data), as well as in gel diffusion experiments (3). This MAb did not inhibit the binding of the two MAbs specific for antigenic site I and showed only unidirectional complete blocking of the MAbs specific for the antigenic site II. These findings suggest that the epitope recognized by MAb H 12 should be considered as a sterically distinct antigenic determinant (site III).

On the other hand, competition-binding ELISA showed that a large number of cross-reacting epitopes are present on the adenovirus hexon. At least seven epitope clusters on the antigenic site II determined by fifteen MAbs show some similarity to each other on the basis of different kinds of complete or mutual unidirectional inhibition patterns. The cause of the nonreciprocal (unidirectional or one-way) inhibition could be a steric change of the epitope due to the attached MAb, which than prevents partially the binding of the labelled MAbs. Neighbouring epitopes may be located in a groove on the surface of the antigenic site, therefore the binding of the competing MAb could sterically block the access of the labelled MAb specific for a different
epitope in the groove (7, 8, 10, 15). A further explanation could be the differences due to antibody avidities (16).

The analysis of the antigenic structure of the adenovirus hexon leads to two major conclusions. On the one hand, the nine epitopes (epitope clusters) identified by eighteen MAbs can be located on three distinct presumably nonoverlapping antigenic sites. On the other hand, the data suggest that seven epitope clusters identified by fifteen MAbs on the antigenic site II contain partially overlapping epitopes and may be a part of a large single immunodominant region on the AV 1 hexon as well as on the heterologous hexon types, as suggested by the experiments with heterologous hexons.

Acknowledgements

The skilled assistance of Miss Z. Bakonyi and Mrs. M. Sóskuti is highly appreciated.

References

1. AVRAMEAS S, TERNYNCK T (1971) Peroxidase labelled antibody and FAb conjugates with enhanced intracellular penetration. Immunochemistry 8: 1175–1179
2. ADÁM É, LENGYEL A, TAKÁCS M, ERDEI J, FACHET J, NÁSZ I (1986) Grouping of monoclonal antibodies to adenovirus hexons by their cross-reactivity. Arch Virol 87: 61–71
3. ADÁM É, NÁSZ I, LENGYEL A, ERDEI J, FACHET J (1985) Differentiation of adenovirus hexon epitopes with monoclonal antibodies by gel diffusion assay. Mol Immunol 22: 967–971
4. CAMMACK N, GOULD EA (1986) Topographical analysis of epitope relationship on the envelope glycoprotein of Yellow Fever 17 D vaccine and the wild type Asibi parent virus. Virology 150: 333–341
5. CEPKO CL, WHEATSTONE CA, SHARP PA (1983) Adenovirus hexon monoclonal antibody that is group specific and potentially useful as a diagnostic reagent. J Clin Microbiol 17: 360–364
6. CHUAT JC, GRCE M, PILON C, GUILLEMIN MC (1985) Monoclonal antibodies to murine retrovirus protein p30. J Gen Virol 66: 1855–1862
7. DESHPANDE KL, PORTNER A (1984) Structural and functional analysis of Sendai virus nucleocapsid protein NP with monoclonal antibodies. Virology 139: 32–42
8. JACKSON DC, WEBSTER RG (1982) A topographic map of the enzyme active center and antigenic sites on the neuraminidase of influenza virus A/Tokyo/3/67 (H 2 H 2). Virology 123: 69–77
9. LENGYEL A, NÁSZ I (1970) Soluble components of adenovirus type 8. J Virol 6: 406–413
10. LUBECK M, GERHARD W (1982) Conformational changes at topographically distinct antigenic sites on the influenza A/PR/8/34 virus molecule are included by binding of monoclonal antibodies. Virology 118: 1–7
11. NÁSZ I, LENGYEL A, CSEBÉI I (1972) Comparative studies of adenovirus hexon antigens. Arch Ges Virusforsch 36: 80–92
12. NORBY E, WADELL G (1969) Immunological relationship between hexon of certain human adenoviruses. J Virol 4: 663–670
13. PETTERSON U, WADELL G (1985) Antigenic structure of adenoviruses. In: VAN REGENMORTEL MHV, NEURATH AR (eds) Immunochemistry of viruses. The basis for serodiagnosis and vaccines. Elsevier, Amsterdam, pp 295–323
14. RUSSELL WC, PATEL G, PRECIOUS B, SHARP PA (1981) Monoclonal antibodies against adenovirus type 5: preparation and preliminary characterization. J Gen Virol 56: 393–408
15. SATO TA, FUKUDA A, SUGIURA A (1985) Characterization of major structural proteins of measles virus with monoclonal antibodies. J Gen Virol 66: 1397–1409
16. STONE MR, NOVINSKI RC (1980) Topological mapping of murine leukemia virus proteins by competition-binding assays with monoclonal antibodies. Virology 100: 370–381
17. WEDE H, DÖBIES R, WEGE H (1984) Hybridoma antibodies to the murine coronavirus JHM: characterization of epitopes on the peplomer protein (E 2). J Gen Virol 65: 1931–1942
18. WIGAND R, BARTHA A, DREIZIN RS, ESCHE H, GINSBERG HS, GREEN M, HIERHOLZER JC, KALTER SS, MCFERRAN JB, PETTERSON U, RUSSELL WC, WADELL G (1982) Adenoviridae: second report. Intervirology 18: 169–176
19. YEWDELL JW, GERHARD W (1981) Antigenic characterization of viruses by monoclonal antibodies. Ann Rev Microbiol 35: 185–206

Authors’ address: Dr. I. Nász, Institute of Microbiology, Semmelweis University Medical School, Nagyvárad tér 4, H-1089 Budapest, Hungary

Received June 6, 1986